quinazolines has been researched along with Impotence in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altay, AB; Apaydin, E; Bademkiran, F; Cikili, N; Semerci, MB; Turna, B; Umul, M | 1 |
| Bloodworth, BC; Ge, X; Koh, HL; Lin, L; Low, MY; Yin, SO; Zou, P | 1 |
| Ahn, SK; Choi, H; Choi, NS; Han, CK; Hwang, IC; Im, DS; Kim, SJ; Kim, SW; Kim, YH; Lee, HW; Lee, J; Lee, KJ; Lee, SS; Moon, SK; Yoon, JH | 1 |
| Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC | 1 |
| Belgrano, E; Bucci, S; De Giorgi, G; Liguori, G; Maio, G; Ocello, G; Ollandini, G; Pomara, G; Trombetta, C; Vecchio, D | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Ahn, SK; Choi, H; Choi, NS; Hwang, IC; Im, DS; Kim, SJ; Kim, SW; Kim, YH; Lee, HW; Lee, J; Lee, KJ; Lee, SS; Moon, SK | 1 |
| Akarasakul, D; Choeypunt, N; Chotikawanich, E; Kongwiwatanakul, S; Leungwattanakij, S; Lojanapiwat, B; Noppakulsatit, P; Permpongkosol, S; Petchpaibuol, T; Pripatnanont, C; Tantiwong, A; Tongbai, T; Wanamkang, T; Watanachote, D | 1 |
| Krilad-O-Larn, S; Permpongkosol, S; Ratana-O-Larn, K | 1 |
| Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD | 1 |
| Larson, TR | 1 |
| Barras, M; Palea, S | 1 |
| Nordling, J; Roehrborn, CG; Van Kerrebroeck, P | 1 |
| Michel, MC | 1 |
| Seftel, A | 1 |
| de la Rosette, JJ; Michel, MC; van Dijk, MM | 1 |
| O'Leary, MP | 1 |
| Gonzalez, RR; Kaplan, SA; Te, AE | 1 |
| Sciarra, A | 1 |
| Alexandre, L; Behr-Roussel, D; Charles Tremeaux, J; Combes, M; Giuliano, F; Gorny, D; Oger, S | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ | 1 |
| Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D | 1 |
| Claes, H; De Reijke, TM; Folkestad, B; Höfner, K; Speakman, MJ | 1 |
| Krupinski, J; Macor, JE; Normandin, D; Pongrac, R; Rotella, DP; Seliger, L; Sun, Z; Zhu, Y | 1 |
| Hayakawa, H; Hirata, Y; Homma, Y; Horie, S; Kawabe, K; Kitamura, T; Minowada, S; Nagai, R; Nagata, D; Nishimatsu, H; Ohta, N; Satonaka, H; Suzuki, E; Takeuchi, T | 1 |
4 review(s) available for quinazolines and Impotence
| Article | Year |
|---|---|
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Humans; Laser Coagulation; Male; Middle Aged; Minimally Invasive Surgical Procedures; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Transurethral Resection of Prostate | 2003 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation; Erectile Dysfunction; Humans; Libido; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
6 trial(s) available for quinazolines and Impotence
| Article | Year |
|---|---|
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Quinazolines; Tadalafil; Treatment Outcome; Urologic Diseases | 2009 |
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Erectile Dysfunction; Humans; Male; Middle Aged; Nocturia; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Thailand | 2010 |
Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Thailand; Urination; Urologic Diseases | 2011 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2003 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Treatment Outcome; Urination Disorders | 2007 |
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Humans; Incidence; Libido; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Treatment Outcome; Urethral Obstruction | 1999 |
15 other study(ies) available for quinazolines and Impotence
| Article | Year |
|---|---|
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass Index; Erectile Dysfunction; Humans; Lipids; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Testosterone | 2014 |
Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplement.
Topics: Capsules; Chromatography, Liquid; Dietary Supplements; Drug Contamination; Erectile Dysfunction; Humans; Imidazoles; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Structure; Phosphodiesterase Inhibitors; Quinazolines; Spectrophotometry, Ultraviolet | 2008 |
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Topics: Combinatorial Chemistry Techniques; Erectile Dysfunction; Humans; Male; Molecular Structure; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Quinazolines; Structure-Activity Relationship | 2008 |
Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blotting, Western; Erectile Dysfunction; Immunohistochemistry; Male; Muscle Contraction; Muscle Relaxation; Nitric Oxide Synthase; Penile Erection; Penis; Quinazolines; Rats; Rats, Sprague-Dawley; Urinary Bladder Neck Obstruction | 2008 |
Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).
Topics: Administration, Oral; Animals; Carbamates; Catalytic Domain; Computer Simulation; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Quinazolines; Rabbits; Rats | 2010 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Taiwan; Treatment Outcome | 2012 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erection; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Rabbits; Sildenafil Citrate; Sulfones | 2003 |
Ejaculatory dysfunction and alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Erectile Dysfunction; Humans; Male; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Prognosis; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders | 2005 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Prevalence; Prostatic Hyperplasia; Purines; Quality of Life; Quinazolines; Risk Factors; Sildenafil Citrate; Sulfones; Urination Disorders | 2007 |
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Carbolines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erectile Dysfunction; Humans; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide; Penile Erection; Phosphodiesterase Inhibitors; Quinazolines; Tadalafil | 2008 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturia; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2008 |
[Permanent therapy of chronic cardiac insufficiency with prazosin].
Topics: Adult; Erectile Dysfunction; Female; Heart Failure; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Quinazolines; Time Factors | 1981 |
N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Imidazoles; In Vitro Techniques; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Purinones; Quinazolines; Rabbits; Sildenafil Citrate; Structure-Activity Relationship; Sulfones | 2000 |
Effects of intracavernous administration of adrenomedullin on erectile function in rats.
Topics: Adrenomedullin; Animals; Arginine; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Erectile Dysfunction; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Penile Erection; Peptides; Phosphodiesterase Inhibitors; Piperidines; Quinazolines; Rats; Rats, Wistar | 2001 |